Indications & Uses
Wandara is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Dosage Adults (over 12 years): 1 g given once a day. Pediatric (3 months to 12 years): 15 mg/kg twice daily (not to exceed 1 g/day). Ertapenem may be given by IV infusion or IM injection. When given intravenously, it should be infused over 30 minutes. IM administration of Ertapenem may be used as an alternative to IV administration for the treatment of infections where intramuscular therapy is appropriate. The usual duration of therapy with Ertapenem is 3 to 14 days, but this varies with the type of infection and the causative pathogen(s). When clinically indicated, a switch to a suitable oral antimicrobial may be made once clinical improvement has been observed. Prophylaxis of surgical site infection following elective colorectal surgery: To prevent surgical site infections after surgery in adults, the recommended dosage is 1 g IV given as a single intravenous dose 1 hour before the surgical incision. Patients with renal insufficiency: Ertapenem may be used to treat infections in adult patients with renal insufficiency. In patients whose creatinine clearance is above 30 mL/min, no dosage adjustment is necessary. Adult patients with advanced renal insufficiency (creatinine clearance of 30 mL/min or less), including those on haemodialysis, should receive 500 mg daily. There are no data in paediatric patients with renal insufficiency. Patients on haemodialysis: If Ertapenem is given at least 6 hours before haemodialysis, no supplementary dose is needed. When adult patients on haemodialysis are given Ertapenem within 6 hours before haemodialysis, a supplementary 30% dose is recommended after the haemodialysis session. There are no data in patients undergoing peritoneal dialysis or haemofiltration. There are no data in paediatric patients on haemodialysis. No dosage adjustment is recommended in patients with impaired hepatic function.
Side Effects
Most side effects reported in clinical studies were mild to moderate. The most common drug-related side effects seen during parenteral (injection) treatment with Erpen are headache, infused vein complication, phlebitis/thrombophlebitis, diarrhoea, nausea and vomiting. Other uncommon side effects include dizziness, somnolence, insomnia, seizure, confusion, extravasation, hypotension, dyspnoea, oral candidiasis, constipation, acid regurgitation, C. difficile-associated diarrhoea, dry mouth, dyspepsia, anorexia, erythema, pruritus, abdominal pain, taste perversion, asthenia/fatigue, candidiasis, oedema/swelling, fever, pain, chest pain and vaginal pruritus.
Cautions & Contraindications
Warnings & Precautions
Before starting Erpen, your doctor should ask carefully about any previous allergic reactions to penicillins, cephalosporins, other beta-lactam antibiotics, or other allergens. If an allergic reaction to Erpen occurs, the drug should be stopped immediately. Serious anaphylactic reactions need immediate emergency treatment. As with other antibiotics, prolonged use of Erpen may lead to the overgrowth of organisms that are not susceptible to it. The patient's condition should be reassessed regularly. If a superinfection develops during treatment, appropriate measures should be taken. Pseudomembranous colitis has been reported with nearly all antibacterial agents, including Erpen, and can range from mild to life-threatening. This diagnosis should therefore be considered in patients who develop diarrhoea after taking antibacterial agents. Studies indicate that a toxin produced by Clostridium difficile is a primary cause of "antibiotic-associated colitis".
Contraindications
Ertapenem must not be given to patients with a known hypersensitivity to any component of this product, to other drugs in the same class, or to patients who have had anaphylactic reactions to beta-lactams. Because lidocaine HCl is used as the diluent, intramuscular injection of Ertapenem must not be given to patients with a known hypersensitivity to amide-type local anaesthetics, or to patients with severe shock or heart block.